Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015

Core Insights - The U.S. Patent and Trademark Office has issued Patent No. 12,458,647 for ERAS-0015, providing intellectual property protection until at least 2043, which may be extended further [1][2] - Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are expected in 2026 [1][2] Summary by Sections ERAS-0015 - ERAS-0015 is an oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling, showing 8-21 times higher binding affinity to cyclophilin A compared to the most advanced competitor [3] - It exhibits approximately 5 times greater potency in RAS inhibition and demonstrates superior in vivo antitumor activity at lower doses [3] - The drug is currently being evaluated in the AURORAS-1 Phase 1 trial for patients with RAS-mutant solid tumors [3] ERAS-4001 - ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor with a promising profile against KRAS G12X mutations and wildtype amplifications [4] - It has shown potent activity against both active and inactive states of KRAS with single-digit nanomolar IC50s and induced tumor regression in multiple KRAS-mutant models [4] - The drug is being evaluated in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors [4] Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company aims to create novel therapies and combination regimens to comprehensively target the RAS/MAPK pathway [5]